Sign Up to like & get
recommendations!
0
Published in 2019 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyz149
Abstract: BACKGROUND Adjuvant capecitabine and oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients with moderate renal impairment, the incidence of CAPOX-related adverse events (AEs) and the rate of early discontinuation are…
read more here.
Keywords:
renal function;
colon cancer;
clcr;
clcr group ... See more keywords